New chemo drug shows promise for tough testicular cancers
NCT ID NCT02115165
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a chemotherapy drug called cabazitaxel in 34 men with advanced testicular cancer that had already been treated with at least two other chemotherapies. The goal was to see if cabazitaxel could shrink tumors, including those that spread to the brain. Cabazitaxel is a newer type of taxane drug that may work better and cause fewer nerve problems than older options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabazitaxel
What this could lead to
If it works, this could offer a new treatment option for men with advanced testicular cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is a small, early-phase trial with only 34 participants. It may not show enough benefit to become a standard treatment, and cabazitaxel can cause side effects like low blood counts and fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SEMINOMATOUS GERM-CELL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val de Marne, 94805, France